Melasma
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Ew rewşek hevpar e ku di destpêka salên 40-an de di jinên Asyayî de tê dîtin. Birîna dorpêçkirî ya di wêneyê de ji melasmayê bêtir nêzî lentigo ye.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Di van demên dawî de, low-fluence Q-switched Nd:YAG (LFQSNY) lazer ji bo dermankirina melasmayê, nemaze li Asyayê, populer bûye. Kurtekirina lêkolînên cihêreng dijwar bû, lê LFQSNY li gorî dermanên kevneşopî bi gelemperî ji bo melasma bandorker û ewledar xuya dike. Lêbelê, hin bûyerên hîpopîgmentasyona motle wekî bandorek alîgirê LFQSNY hatine ragihandin, dibe ku ji ber enerjiya lazerê ya bilind. Bikaranîna dijwar a LFQSNY di heman demê de dikare bibe sedema hîperpîgmentasyona ji iltîhaba, nemaze di rengên çermê tarî de.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Pirsgirêkên pigmentasyonê pir caran di lênêrîna bingehîn de têne dîtin. Cûreyên gelemperî yên nexweşiyên hîperpîgmentasyonê post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots hene.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Melasma ji bo demek diyarkirî bi dermankirina lazerê nayê çareser kirin, ji ber ku ew nexweşiyek e ku tê de pigment bi berdewamî tê hilberandin. Acîda Tranxenemic ji bo kêmkirina pigmentasyonê çêtir dibe alîkar.
○ Demankirinî
Li hin welatan (mînak Japonya, Kore), asîda tranexamîk a devkî li ser derman heye û bi bandor e. Krema melasmayê ya bi asîda tranexamîk û azelaîk asîdê dibe ku hinekî alîkar be.
Dibe ku hîdroquinone ji bo dermankirina hîperpîgmentasyonê bi cihkî were bikar anîn, lê FDA hilberên OTC yên ku hîdroquinone hene ji sala 2020-an ve rawestand.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma